Verici Dx has completed patient enrolment of its clinical validation study of Clarava and Tuteva. Achieving this milestone is in line with expectations set at IPO and adds confidence to our expectation that the study will complete around year-end 2021 with results expected in early 2021. We reiterate our positive stance on Clarava and Tuteva, and their potential to become the future standard-of-care of predicting and detecting organ transplant rejection.
31 Aug 2021
Validation study fully enrolled
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Validation study fully enrolled
Verici Dx Plc (VRCI:LON) | 8.0 0 0.0% | Mkt Cap: 19.4m
- Published:
31 Aug 2021 -
Author:
Edward Thomason -
Pages:
3
Verici Dx has completed patient enrolment of its clinical validation study of Clarava and Tuteva. Achieving this milestone is in line with expectations set at IPO and adds confidence to our expectation that the study will complete around year-end 2021 with results expected in early 2021. We reiterate our positive stance on Clarava and Tuteva, and their potential to become the future standard-of-care of predicting and detecting organ transplant rejection.